N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation
directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane
I 131 may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of giving vorinostat
together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium